Evonetix

Evonetix is a biotechnology company that develops a synthetic biology platform for DNA synthesis and gene assembly. The company's proprietary technology uses silicon arrays manufactured through semiconductor microfabrication, enabling various miniaturized reaction sites for parallel DNA synthesis. The platform is designed to synthesize genes with high GC content and assemble long DNA sequences with high fidelity. Evonetix's approach integrates thermal control of individual reaction sites on the silicon array, allowing precise control over DNA synthesis chemistry and enabling error correction during the assembly process. The technology aims to democratize gene synthesis for applications in drug discovery, vaccine development, agricultural biotechnology, and industrial biotechnology. Founded in 2015 and headquartered in Saffron Walden, United Kingdom, Evonetix has raised approximately $70 million in Series B funding from investors including DCVC, Draper Esprit, Cambridge Consultants, Rising Tide Fund, Civilization Ventures, Morningside, Foresite Capital, Providence Equity Partners, Molten Ventures, and Providence Investment Company.